Kira Pharmaceuticals Presents Updated Data of Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH) at American Society of Hematology (ASH) 2024 Demonstrating Long-Term Safety and Efficacy
CAMBRIDGE, Mass., Dec. 10, 2024 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced positive long-term results from its Phase 2